Regeneron Pharmaceuticals CEO Leonard Schleifer's 2020 pay jumps 531% to $135M
Regeneron Pharmaceuticals reports 2020 executive compensation
By ExecPay News
Published: April 23, 2021
Regeneron Pharmaceuticals reported fiscal year 2020 executive compensation information on April 23, 2021.
In 2020, five executives at Regeneron Pharmaceuticals received on average a compensation package of $59M, a 339% increase compared to previous year.
Average pay of disclosed executives at Regeneron Pharmaceuticals
Leonard S. Schleifer, Chief Executive Officer, received $135M in total, which increased by 531% compared to 2019. 96% of Schleifer's compensation, or $130M, was in stock awards. Schleifer also received $3.6M in non-equity incentive plan, $1.5M in salary, as well as $302K in other compensation.
George D. Yancopoulos, Chief Scientific Officer, received a compensation package of $134M, which increased by 550% compared to previous year. 97% of the compensation package, or $130M, was in stock awards.
Andrew J. Murphy, Executive Vice President, Research, earned $11M in 2020, a 16% increase compared to previous year.
Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply, received $8.7M in 2020, which increases by 11% compared to 2019.
Robert E. Landry, Chief Financial Officer, earned $6.2M in 2020, a 22% decrease compared to previous year.
Related executives
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer
George Yancopoulos
Regeneron Pharmaceuticals
Chief Scientific Officer
Robert Landry
Regeneron Pharmaceuticals
Chief Financial Officer
Daniel Van Plew
Regeneron Pharmaceuticals
Executive Vice President and General Manager, Industrial Operations and Product Supply
Andrew Murphy
Regeneron Pharmaceuticals
Executive Vice President, Research
You may also like
Source: SEC filing on April 23, 2021.